A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in China

Connect Investigative Site 33, Hefei

Connect Investigative Site 01, Beijing

Connect Investigative Site 02, Beijing

Connect Investigative Site 03, Beijing

Connect Investigative Site 17, Beijing

Connect Investigative Site 47, Beijing

Connect Investigative Site 28, Chongqing

Connect Investigative Site 29, Chongqing

Connect Investigative Site 30, Chongqing

Connect Investigative Site 36, Chongqing

Connect Investigative Site 38, Fuzhou

Connect Investigative Site 07, Guangzhou

Connect Investigative Site 25, Guangzhou

Connect Investigative Site 37, Guangzhou

Connect Investigative Site 46, Guangzhou

Connect Investigative Site 48, Guangzhou

Connect Investigative Site 43, Shaoguan

Connect Investigative Site 52, Shenzhen

Connect Investigative Site 41, Haikou

Connect Investigative Site 42, Haikou

Connect Investigative Site 20, Zhengzhou

Connect Investigative Site 32, Shijiazhuang

Connect Investigative Site 45, Nanyang

Connect Investigative Site 54, Xinxiang

Connect Investigative Site 49, Wuhan

Connect Investigative Site 35, Baotou

Connect Investigative Site 26, Nanjing

Connect Investigative Site 18, Suzhou

Connect Investigative Site 55, Wuxi

Connect Investigative Site 10, Zhenjiang

Connect Investigative Site 34, Nanchang

Connect Investigative Site 44, Yinchuan

Connect Investigative Site 11, Jinan

Connect Investigative Site 50, Jinan

Connect Investigative Site 51, Jinan

Connect Investigative Site 12, Yantai

Connect Investigative Site 08, Taiyuan

Connect Investigative Site 24, Taiyuan

Connect Investigative Site 39, Yuncheng

Connect Investigative Site 05, Tianjin

Connect Investigative Site 06, Tianjin

Connect Investigative Site 13, Shanxi

Connect Investigative Site 22, Ürümqi

Connect Investigative Site 53, Qujing

Connect Investigative Site 14, Hangzhou

Connect Investigative Site 15, Hangzhou

Connect Investigative Site 16, Hangzhou

Connect Investigative Site 19, Jinhua